BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 2
• 3
• 4
• 5
• 6
• 7

• Press Releases

  Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

  November 5, 2025

   · 

  7 min read
• Press Releases

  Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

  November 5, 2025

   · 

  9 min read
• Press Releases

  Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek®

  November 5, 2025

   · 

  4 min read
• Press Releases

  Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users

  November 5, 2025

   · 

  5 min read
• Press Releases

  Ankyra Announces Publication of Phase 1 Clinical Data, and Will Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

  November 5, 2025

   · 

  4 min read
• Press Releases

  $1M Grant from the Maryland Stem Cell Research Fund (MSCRF) Powers Novel Adipose Tissue Allograft Therapy for Osteoarthritis

  November 5, 2025

   · 

  4 min read
• Press Releases

  Colossal Biosciences Acquires Viagen, the Leader in Animal Cloning

  November 5, 2025

   · 

  6 min read
• Press Releases

  Radiant Biotherapeutics to Present New Data from Lead Oncology Program at SITC 2025 Annual Meeting

  November 5, 2025

   · 

  2 min read
• Press Releases

  Meitheal Pharmaceuticals Receives Approval from the US Food and Drug Administration for CONTEPO™ (fosfomycin) for injection in Patients ≥ 18 Years Having Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP)

  November 5, 2025

   · 

  10 min read
• Press Releases

  Opna Bio Announces 2025 ASH Presentations Highlighting Preclinical Data from Novel Protein Degrader Program and Updated Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Advanced Myelofibrosis

  November 5, 2025

   · 

  3 min read